Article in Nature Biotechnology about our new name and plans for the future (subscription needed to read full text).
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.